Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 361 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor markers Clear all

Conditions: Lung; Node, Adenocarcinoma of Lung
Interventions: DetermaRX; Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Laryngeal Verrucous Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oral Cavity Verrucous Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Verrucous Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Verrucous Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Laryngeal Verrucous Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions: Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years to 79 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan

Conditions: Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions: Systemic therapy, StrataNGS; Other · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
Interventions: enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Cancer
Interventions: Fiducial marker placement; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: IFNα2b, PEG- IFNα2b; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Mastectomy; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions: Magnetic Resonance Imaging; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more

Conditions: Urinary Bladder Neoplasms
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Orange, California

Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions: Secretin, MRI, Tumor marker gene test with CA19-9; Drug · Diagnostic Test · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 9
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Stage III and IV Glioma Patients
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Blood Collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Cervical Intraepithelial, Neoplasia, CIN
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 3,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2020
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Specimen, Biospecimen Collection, Archived Biospecimen Collection, Medical Chart Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: gene expression analysis, polymorphism analysis, protein expression analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions: Observational Cohort; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasm
Interventions: Everolimus, Letrozole; Drug
Lead sponsor: Sinai Hospital of Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Cancer
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Cancer
Interventions: Collect Blood and Survey Instruments; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: Genomic Health®, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma
Interventions: PET/CT, Laboratory Testing, Safety Testing, Immunohistochemistry staining, F-18-ISO; Radiation · Other · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions: Cessation of anti-HER2 treatment; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 13
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more

Search by objective public record fields.

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

Pilot Study of IFN α2b for Melanoma Patients

Markers for Predicting Risk of Breast Cancer in Women of Different Races

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Molecular Biosensors for Detection of Bladder Cancer

The Cancer of the Pancreas Screening-5 CAPS5)Study

CTCs for High Grade Glioma

Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer

Cervical Cancer Early Endpoints and Determinants

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

Predicting Disease Progression and/or Recurrence in Cancer

Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls

Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer

Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

STOP-HER2: Stopping Trastuzumab in HER2+ MBC